#JPM23: BeiGene CEO John Oyler on the com­pa­ny's big am­bi­tions

BeiGene CEO John Oyler and End­points News Ex­ec­u­tive Ed­i­tor Drew Arm­strong spoke one-on-one about where the drug­mak­er is head­ed in its quest to be­come a di­ver­si­fied multi­na­tion­al, and what it will take to get there. This tran­script has been edit­ed for brevi­ty and clar­i­ty.

Drew Arm­strong:

I am joined to­day by BeiGene CEO John Oyler. By way of in­tro­duc­tion, John and I met about a lit­tle over three years ago for the first time in Bei­jing, when I was do­ing some re­port­ing. I got to trav­el around the coun­try and I had this huge note­book full of re­port­ing on in­ter­est­ing things that his com­pa­ny was do­ing and some of the oth­er com­pa­nies were do­ing over there. And I came back to the states ready to write a great mag­a­zine sto­ry about BeiGene and about in­no­va­tion that was hap­pen­ing glob­al­ly. And then I think we all know what hap­pened about a week and a half af­ter I re­turned, in Jan­u­ary of 2020. And un­for­tu­nate­ly that work nev­er saw the light of day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.